{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Disease&page=38",
    "query": {
      "condition": "Primary Disease",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 6316,
    "total_pages": 632,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Disease&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Primary+Disease&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T08:29:29.719Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01151787",
      "title": "Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "cyclobenzaprine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kennedy Medical Group",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2010-07",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-07-25",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 1,
      "location_summary": "Cherry Hill, New Jersey",
      "locations": [
        {
          "city": "Cherry Hill",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01151787"
    },
    {
      "nct_id": "NCT03697187",
      "title": "Patient Registry to Evaluate the Real-world Safety of Ruconest®",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "rhC1INH",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharming Technologies B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 152,
      "start_date": "2018-06-30",
      "completion_date": "2021-07-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-05",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03697187"
    },
    {
      "nct_id": "NCT03721393",
      "title": "Data Collection - Of Syncope Tilt Table Testing Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Orthostatic Hypotension",
        "Reflex Syncope"
      ],
      "interventions": [
        {
          "name": "Wearable heart monitor",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Boston Scientific Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2019-10-04",
      "completion_date": "2023-05-08",
      "has_results": false,
      "last_update_posted_date": "2023-08-02",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03721393"
    },
    {
      "nct_id": "NCT03286114",
      "title": "Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2017-12-21",
      "completion_date": "2021-04-28",
      "has_results": true,
      "last_update_posted_date": "2025-05-11",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03286114"
    },
    {
      "nct_id": "NCT05107635",
      "title": "Inappropriate Sinus Tachycardia Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Inappropriate Sinus Tachycardia",
        "Postural Tachycardia Syndrome"
      ],
      "interventions": [
        {
          "name": "AtriCure Commercially Available Devices",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "AtriCure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 500,
      "start_date": "2022-03-01",
      "completion_date": "2030-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 12,
      "location_summary": "Loma Linda, California • Palo Alto, California • Redwood City, California + 9 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107635"
    },
    {
      "nct_id": "NCT02423408",
      "title": "Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tension-Type Headache"
      ],
      "interventions": [
        {
          "name": "TNX-201",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tonix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 165,
      "start_date": "2015-06",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-11",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 10,
      "location_summary": "San Jose, California • DeLand, Florida • Stockbridge, Georgia + 7 more",
      "locations": [
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02423408"
    },
    {
      "nct_id": "NCT00635076",
      "title": "A Study to Assess the Long-term Use of Alprazolam Extended Release (XL) in the Treatment of Adolescents With Panic Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Panic Disorder"
      ],
      "interventions": [
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "alprazolam XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "13 Years to 17 Years"
      },
      "enrollment_count": 3,
      "start_date": "2004-07",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 3,
      "location_summary": "Eugene, Oregon • San Antonio, Texas • Middleton, Wisconsin",
      "locations": [
        {
          "city": "Eugene",
          "state": "Oregon"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Middleton",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635076"
    },
    {
      "nct_id": "NCT00048776",
      "title": "Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Raynaud's Disease"
      ],
      "interventions": [
        {
          "name": "Pletal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka America Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "5 Years to 16 Years"
      },
      "enrollment_count": 75,
      "start_date": "2001-10",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2005-07-19",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 19,
      "location_summary": "Anchorage, Alaska • Fresno, California • Madera, California + 16 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048776"
    },
    {
      "nct_id": "NCT00844168",
      "title": "Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Primary Hepatocellular Carcinoma",
        "Advanced Adult Primary Liver Cancer",
        "Localized Resectable Adult Primary Liver Cancer",
        "Localized Unresectable Adult Primary Liver Cancer",
        "Recurrent Adult Primary Liver Cancer"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2009-01",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-03-27",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00844168"
    },
    {
      "nct_id": "NCT00600210",
      "title": "Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Leo W. Jenkins Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2008-01",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2017-08-23",
      "last_synced_at": "2026-11-21T08:29:29.719Z",
      "location_count": 1,
      "location_summary": "Greenville, North Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600210"
    }
  ]
}